Eiko Life Sciences Reports 281% Surge in Q2 Profit, Revenue Up 19%

EIKO Lifesciences , a player in the specialty chemicals and pharma intermediates segment, has reported a significant boost in its financial performance for the quarter ended September 30, 2025. The company's unaudited financial results reveal a substantial increase in profitability and steady revenue growth.

Key Financial Highlights

Metric	Q2 FY2026	Q2 FY2025	YoY Change
Net Profit	₹81.76	₹20.81	281% ↑
Revenue from Operations	₹919.74	₹773.92	19% ↑
Earnings Per Share (EPS)	₹0.60	₹0.16	275% ↑

Profit Surge

EIKO Lifesciences witnessed a remarkable 281% year-on-year increase in net profit, reaching ₹81.76 lakhs for the quarter, compared to ₹20.81 lakhs in the same period last year. This substantial growth in profitability underscores the company's improved operational efficiency and market performance.

Revenue Growth

The company's revenue from operations grew by 19% year-on-year, rising to ₹919.74 lakhs from ₹773.92 lakhs in the corresponding quarter of the previous fiscal year. This growth indicates a robust demand for the company's products in the specialty chemicals and pharma intermediates segment.

Half-Year Performance

For the half-year period ended September 30, 2025, EIKO Lifesciences reported a profit of ₹150.98 lakhs, a significant improvement from ₹55.49 lakhs in the previous year. This represents a 172% increase in profitability for the six-month period.

Earnings Per Share

The company's earnings per share (EPS) for the quarter improved substantially to ₹0.60, up from ₹0.16 in the same quarter of the previous year, reflecting a 275% increase. This improvement in EPS directly benefits the company's shareholders.

Board Approval

The Board of Directors of EIKO Lifesciences approved these unaudited financial results in a meeting held on October 31, 2025. The results have undergone a limited review by the company's statutory auditors.

Consolidated Performance

On a consolidated basis, which includes the performance of its subsidiaries and associates, EIKO Lifesciences reported even stronger results:

Metric	Q2 FY2026 (Consolidated)	YoY Change
Revenue from Operations	₹1,167.17	43% ↑
Net Profit	₹128.47	356% ↑

The consolidated figures show a 43% year-on-year increase in revenue and a 356% surge in net profit, indicating strong performance across the group's businesses.

EIKO Lifesciences' robust financial performance in Q2 FY2026 reflects its strong position in the specialty chemicals and pharma intermediates market. The significant growth in both standalone and consolidated results suggests effective strategy execution and favorable market conditions for the company's products.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.80%	+0.38%	-18.51%	+0.58%	-15.51%	+68.50%

EIKO Lifesciences Limited announced its unaudited financial results for the first quarter, along with several key corporate updates, in a board meeting held on July 29, 2025.

Financial Highlights

For Q1 (April-June 2025), Eiko LifeSciences reported:

Consolidated revenue from operations of ₹1,071.15 lakhs, compared to ₹1,075.04 lakhs in Q1 of the previous year
Consolidated profit after tax of ₹111.74 lakhs, a significant increase from ₹37.13 lakhs in the same quarter last year
Earnings per share (EPS) of ₹0.66, up from ₹0.29 in Q1 of the previous year

The company's specialty and fine chemicals segment generated revenue of ₹840.22 lakhs, while the logistics business contributed ₹230.93 lakhs.

Board Changes and Appointments

The board announced several changes to its composition:

Mr. Umesh More resigned as Whole Time Director, effective July 29, 2025
Mr. Sumukh Prabhakar Vartak was appointed as additional Whole Time Director for a term of 5 years, subject to shareholder approval
Ms. Kajal Kothari and Mr. Rajkumar Baheti were re-appointed as Independent Directors for second terms of 5 years each, pending shareholder approval

Increase in Authorized Share Capital

The board approved an increase in the company's authorized share capital from ₹14 crore to ₹20 crore. The proposed change will amend the Memorandum of Association, increasing the number of equity shares from 1.4 crore to 2 crore, each with a face value of ₹10. This decision is subject to shareholder approval.

Segment Performance

The company operates in two main segments:

Segment	Revenue (₹ lakhs)	Segment Result (₹ lakhs)
Specialty & Fine Chemicals	840.22	44.42
Logistics Business	230.93	29.73

Outlook

Laxmikant Kabra, Chairman of Eiko LifeSciences, commented on the results: "Our strong performance in Q1 demonstrates the resilience of our core specialty chemicals business and the growing contribution from our logistics segment. The board changes and proposed capital increase position us well for future growth opportunities."

The company will seek shareholder approval for the board appointments and capital increase at its upcoming 48th Annual General Meeting, scheduled for September 5, 2025.

Eiko LifeSciences continues to focus on its twin pillars of specialty chemicals and logistics services, with an eye on expanding its market presence and operational capabilities in both sectors.

Share Transfer and KYC Update

In line with SEBI directives, Eiko LifeSciences has opened a special window for re-lodgement of physical share transfer requests from July 7, 2025, to January 6, 2026. This applies to transfer deeds lodged before April 1, 2019, that were rejected or returned due to deficiencies. The company also reminded physical shareholders to update their PAN, KYC, and nomination details as mandated by SEBI.